DK0802184T3 - N-Benzyl-2-phenylindoler som østrogene midler - Google Patents

N-Benzyl-2-phenylindoler som østrogene midler

Info

Publication number
DK0802184T3
DK0802184T3 DK97302577T DK97302577T DK0802184T3 DK 0802184 T3 DK0802184 T3 DK 0802184T3 DK 97302577 T DK97302577 T DK 97302577T DK 97302577 T DK97302577 T DK 97302577T DK 0802184 T3 DK0802184 T3 DK 0802184T3
Authority
DK
Denmark
Prior art keywords
phenylindoles
benzyl
estrogenic agents
estrogenic
agents
Prior art date
Application number
DK97302577T
Other languages
English (en)
Inventor
Chris P Miller
Bach D Tran
Michael D Collini
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK0802184T3 publication Critical patent/DK0802184T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK97302577T 1996-04-19 1997-04-15 N-Benzyl-2-phenylindoler som østrogene midler DK0802184T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63397696A 1996-04-19 1996-04-19
US63397296A 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
DK0802184T3 true DK0802184T3 (da) 2002-09-16

Family

ID=27092024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97302577T DK0802184T3 (da) 1996-04-19 1997-04-15 N-Benzyl-2-phenylindoler som østrogene midler

Country Status (23)

Country Link
EP (1) EP0802184B1 (da)
JP (1) JPH1036347A (da)
KR (1) KR970069986A (da)
CN (1) CN1103756C (da)
AR (1) AR006705A1 (da)
AT (1) ATE219485T1 (da)
AU (1) AU718888B2 (da)
BR (1) BR9701879A (da)
CO (1) CO4950540A1 (da)
CZ (1) CZ293065B6 (da)
DE (1) DE69713441T2 (da)
DK (1) DK0802184T3 (da)
EA (1) EA000815B1 (da)
ES (1) ES2179273T3 (da)
HU (1) HUP9700779A1 (da)
ID (1) ID16618A (da)
IL (1) IL120699A0 (da)
NO (1) NO308214B1 (da)
NZ (1) NZ314595A (da)
PT (1) PT802184E (da)
SK (1) SK282765B6 (da)
TW (1) TW397821B (da)
UA (1) UA47413C2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569896B2 (en) * 2000-08-24 2003-05-27 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
AU3894399A (en) * 1998-05-12 1999-11-29 American Home Products Corporation Benzocarbazole and indenoindole derived estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AP1424A (en) * 1998-05-15 2005-06-06 Wyeth Corp 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
EP1080073A1 (en) * 1998-05-15 2001-03-07 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
BR0013943A (pt) * 1999-09-13 2002-05-14 American Home Prod Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis
EP1296674A2 (en) * 2000-07-06 2003-04-02 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
US6509332B2 (en) 2000-07-06 2003-01-21 Wyeth Methods of treating excessive intraocular pressure
WO2002003988A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
AU2001271706A1 (en) * 2000-07-06 2002-01-21 American Home Products Corporation Use of substituted indole compounds for treating breast disorders
AR029539A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Combinaciones de estatinas y agentes estrogenicos
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
JP2004502729A (ja) * 2000-07-06 2004-01-29 ワイス Ｓｓｒｉおよびエストロゲン剤の組み合わせ
EP1401446B1 (en) 2001-05-22 2005-02-09 Eli Lilly And Company Tetrahydroquinolin derivatives for the inhibition of diseases associated with estrogen deprivation or with an aberrant physiological response to endogenous estrogen
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
TW200536845A (en) 2004-04-07 2005-11-16 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
RU2006132180A (ru) 2004-04-07 2008-05-20 Вайет (Us) Кристаллический полиморф базедоксифен ацетата
BRPI0509385A (pt) 2004-04-08 2007-09-18 Wyeth Corp composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP1781289A1 (en) 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
MX2007011453A (es) 2005-04-22 2008-02-12 Alantos Pharmaceuticals Holding Inc Inhibidores de la dipeptidil peptidasa-iv.
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
RS62481B1 (sr) 2015-05-29 2021-11-30 Eisai R&D Man Co Ltd Jedinjenja tetrasupstituisanog alkena i njihova upotreba
WO2017059139A1 (en) 2015-10-01 2017-04-06 Olema Pharmaceuticals, Inc. TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
DK3386500T3 (da) 2015-12-09 2022-12-12 Univ Illinois Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
WO2017162206A1 (zh) * 2016-03-25 2017-09-28 南京明德新药研发股份有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
CN109790141B (zh) 2016-11-28 2021-06-11 卫材 R&D 管理有限公司 吲唑衍生物的盐及其晶体
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3645001B1 (en) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021016254A1 (en) 2019-07-22 2021-01-28 Radius Pharmaceuticals, Inc. Estrogen receptor-modulating compounds
EP4681715A3 (en) 2019-12-20 2026-01-28 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
EP4164653A4 (en) 2020-06-15 2024-06-19 G1 Therapeutics, Inc. MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
BR112023024507A2 (pt) 2021-05-26 2024-02-15 C4 Therapeutics Inc Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
KR20250055538A (ko) 2022-08-03 2025-04-24 브리스톨-마이어스 스큅 컴퍼니 Ret 단백질을 조정하기 위한 화합물
JP2025540906A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質阻害剤
KR20250117789A (ko) 2022-11-04 2025-08-05 브리스톨-마이어스 스큅 컴퍼니 Ret-ldd 단백질 분해제
CN122206684A (zh) 2023-06-30 2026-06-12 默克专利有限公司 用于kras蛋白降解的异双功能化合物
WO2026139448A1 (en) 2024-12-23 2026-07-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3232968A1 (de) * 1981-09-10 1983-06-09 Degussa Ag, 6000 Frankfurt Neue 2-(hydroxy-phenyl)-indole und verfahren zu deren herstellung
DE3821148A1 (de) * 1988-06-23 1989-12-28 Erwin Von Dr Angerer Aminoalkylindole, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9108811D0 (en) * 1991-04-24 1991-06-12 Erba Carlo Spa N-imidazolyl derivatives of substituted indole
RU2061694C1 (ru) * 1991-09-11 1996-06-10 Е.Р.Сквибб энд Санз, Инк., Производные индола
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
WO1993023374A1 (fr) * 1992-05-08 1993-11-25 Otsuka Pharmaceutical Factory, Inc. Derive d'indole
GB9326332D0 (en) * 1993-12-23 1994-02-23 Karo Bio Indole derivatives
ES2122555T3 (es) * 1994-02-22 1998-12-16 Merrell Pharma Inc Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln

Also Published As

Publication number Publication date
EP0802184B1 (en) 2002-06-19
NO971814L (no) 1997-10-20
EA000815B1 (ru) 2000-04-24
AU718888B2 (en) 2000-04-20
EP0802184A1 (en) 1997-10-22
HU9700779D0 (en) 1997-06-30
KR970069986A (ko) 1997-11-07
ATE219485T1 (de) 2002-07-15
JPH1036347A (ja) 1998-02-10
NO971814D0 (no) 1997-04-18
CZ117697A3 (en) 1997-12-17
SK47197A3 (en) 1997-11-05
DE69713441T2 (de) 2002-11-07
ID16618A (id) 1997-10-23
TW397821B (en) 2000-07-11
HK1002862A1 (en) 1998-09-25
CO4950540A1 (es) 2000-09-01
UA47413C2 (uk) 2002-07-15
ES2179273T3 (es) 2003-01-16
NO308214B1 (no) 2000-08-14
CZ293065B6 (cs) 2004-02-18
AR006705A1 (es) 1999-09-08
AU1892197A (en) 1997-10-23
PT802184E (pt) 2002-09-30
BR9701879A (pt) 1998-09-29
SK282765B6 (sk) 2002-12-03
DE69713441D1 (de) 2002-07-25
IL120699A0 (en) 1997-08-14
NZ314595A (en) 2000-04-28
CN1168373A (zh) 1997-12-24
CN1103756C (zh) 2003-03-26
EA199700043A1 (ru) 1997-12-30
HUP9700779A1 (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
NL300416I2 (nl) Estrogene middelen
NO971814D0 (no) Östrogene midler
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
DE69812475D1 (de) Photoresistzusammensetzung
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
EE9800430A (et) Uued ühendid
DE69737373D1 (de) Östroprogestatives Antikonzeptionsmittel
DE69809633D1 (de) Photoresistzusammensetzung
NO971955D0 (no) Nitro-benzamider anvendelige som anti-arrhytmiske midler
DE69706214D1 (de) Photoresistzusammensetzung
DE59708995D1 (de) Esterquats
DE69709582D1 (de) Photolackzusammensetzung
DE69703274D1 (de) Photopolymerisierbare Zusammensetzung
DE69709700D1 (de) Kontrastmittel
NO970689D0 (no) Anti-arrytmiske midler
BR9701895A (pt) Agentes estrogênicos
NO964439L (no) Fôr
FI963725A0 (fi) Bastuugn som vaermar vatten
FI961508A0 (fi) Ledningskanal som ocksao fungerar som foensterbraede
FI960675A0 (fi) Kortslutningsskydd foer en som belastningskoppling fungerande FET-transistor
FI964074A0 (fi) Brandkaempningssystem som anvaender aonga/vaermevaexlare/ackumulatorpanna/golvlistradiator
FI944788A0 (fi) Skidstav som foeljer roerelse
FI964396A0 (fi) Foerfarande foer framstaellning av inredningsytor som bestaor av traespjaelor
FI961646A0 (fi) Foerfarande foer aostadkommande av en masspektrometer som fungerar under tryck
KR970057097U (ko) 탈취기